BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Temozolomide: trial readouts and FDA decisions

3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Sapience Therapeutics, Hangzhou Hanx Biopharmaceuticals, Ltd., Eli Lilly and Company, Philogen S.p.A., BPGbio, JenKem Technology Co., Ltd., BeOne Medicines. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P1/P2Sapience TherapeuticsNCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsGlioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brainactive not recruiting125
2026-12-31 est.P1/P2Hangzhou Hanx Biopharmaceuticals, Ltd.NCT06703255 A Phase 2 Study of HX301 in Patients with High-grade GilomaGliomarecruiting72
2027-02 est.P2Eli Lilly and Company LLYNCT06413706 A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyGliomaactive not recruiting45

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10 est.P1/P2Philogen S.p.A.NCT04443010 Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaGlioblastomarecruiting226
2026-08-25 est.P2BPGbioNCT04752813 A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)Glioblastoma; Glioblastoma Multiformeactive not recruiting50
2026-08-16 est.P2JenKem Technology Co., Ltd.NCT06595186 JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)Glioblastoma Multiforme (GBM)recruiting25
2026-05-23P3BeOne Medicines ONCNCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesAdvanced Malignanciescompleted404

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.